3M panel cancelled
This article was originally published in The Gray Sheet
Lung sealant's previously planned May 12 review by FDA's General & Plastic Surgery Devices Panel is cancelled "by mutual agreement between FDA and the sponsor," according to the agency. 3M characterizes the move as a business decision; the in situ polymerizable sealant remains likely to require panel review at a later date. Results from a five-center, prospective, randomized trial suggesting reduced hospital stays with the sealant are scheduled for May publication in the Annals of Thoracic Surgery (1"The Gray Sheet" April 26, 2004, p. 14)...
You may also be interested in...
3M's lung sealant may shorten hospital stays for lung surgery patients, according to a study led by Mark Allen, MD, Mayo Clinic
India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.